3,517 Shares in Insulet Corporation $PODD Purchased by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 3,517 shares of the medical instruments supplier’s stock, valued at approximately $535,000.

Other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC increased its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet in the fourth quarter valued at approximately $26,000. DV Equities LLC acquired a new stake in shares of Insulet in the fourth quarter worth approximately $28,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the fourth quarter worth approximately $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in shares of Insulet during the fourth quarter worth approximately $29,000.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on PODD. Bank of America reduced their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Piper Sandler lowered their target price on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Barclays dropped their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Robert W. Baird set a $175.00 price target on shares of Insulet in a research note on Thursday, August 6th. Finally, Benchmark decreased their price target on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $195.40.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Insulet Price Performance

NASDAQ:PODD opened at $143.41 on Friday. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The stock has a market cap of $9.95 billion, a PE ratio of 26.81, a P/E/G ratio of 1.13 and a beta of 1.10. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The stock has a 50 day moving average price of $154.47 and a 200 day moving average price of $181.40.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.